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Neuroblastoma is characterised by a lack of TP53 mutations and no other tumour suppressor gene consistently inactivated has yet
been identified in this childhood cancer form. Characterisation of a new gene, denoted APITD1, in the neuroblastoma tumour
suppressor candidate region in chromosome 1p36.22 reveals that APITD1 contains a predicted TFIID-31 domain, representing the
TATA box-binding protein-associated factor, TAFII31, which is required for p53-mediated transcription activation. Two different
transcripts of this gene were shown to be ubiquitously expressed, one of them with an elevated expression in foetal tissues. Primary
neuroblastoma tumours of all different stages showed either very weak or no measurable APITD1 expression, contrary to the level of
expression observed in neuroblastoma cell lines. A reduced pattern of expression was also observed in a set of various tumour types.
APITD1 was functionally tested by adding APITD1 mRNA to neuroblastoma cells, leading to the cell growth to be reduced up to 90%
compared to control cells, suggesting APITD1 to have a role in a cell death pathway. Furthermore, we determined the genomic
organisation of APITD1. Automated genomic DNA sequencing of the coding region of the gene as well as the promoter sequence in
44 neuroblastoma tumours did not reveal any loss-of-function mutations, indicating that mutations in APITD1 is not a common
abnormality of neuroblastoma tumours. We suggest that low expression of this gene might interfere with the ability for apoptosis
through the p53 pathway.
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The chromosomal region 1p36 is commonly deleted in various
paediatric soft tissue tumours including neuroblastoma (Brodeur
et al, 1977, 1981), Wilms’ tumour (Grundy et al, 1994; Steinberg
et al, 2000), embryonal rhabdomyosarcoma (Bridge et al, 2000),
pheochromocytoma (Benn et al, 2000) and germ cell tumours
(Rodriguez et al, 1992; Stock et al, 1995; Bussey et al, 1999; Mostert
et al, 2000; Schneider et al, 2001). Pheochromocytomas and
neuroblastomas are both tumours originating in cells derived from
the neural crest. We have previously narrowed down the shortest
region of overlap of deletions (SRO) in our set of neuroblastoma
tumours to 25cM, between the markers D1S244 and D1S80 on
chromosome 1, through loss of heterozygosity (LOH) studies of a
large number of cases (Martinsson et al, 1995, 1997). A partly
overlapping combined neuroblastoma and germ cell tumour SRO
of 5cM was later defined through the inclusion of a teratoma
tumour with an interstitial 1p deletion (Ejeska ¨r et al, 2001).
Further evidence for the localisation of a neuroblastoma tumour
suppressor gene to this region came from the finding of a 500kb
homozygous deletion within our SRO in a neuroblastoma cell line
(Ohira et al, 2000). Mutation analysis of the coding sequences of all
known genes within this 500kb region indicated a low frequency of
amino-acid changes, implying the presence of yet unidentified
genes in the region which might be involved in the development
and/or progression of neuroblastoma tumours (Ejeska ¨r et al, 2000;
Abel et al, 2002; Krona et al, 2003).
In this paper, we have, by means of in silico mapping, identified
a gene coding for a domain with similarity to the human TATA
box-binding protein-associated factor TAFII31 (locus name TAF9).
The gene is localised to the 500kb hot-spot region in 1p36.2,
between PGD and CORT. TAFII31 has been identified as a critical
protein required for p53-mediated transcriptional activation (Lu
and Levine, 1995). Based on the localisation of this predicted gene,
denoted APITD1 (APoptosis-Inducing, TAF9-like Domain 1), and
the fact that TP53 mutations are rare in neuroblastoma tumours
(Imamura et al, 1993; Komuro et al, 1993; Vogan et al, 1993; Hosoi
et al, 1994), we hypothesised that loss of function for APITD1
could be a way for tumour cells to overcome the cell growth-
regulating properties of the p53 pathway.
In conclusion, we have characterised a new gene, which
might be a member of the proteins involved in cell cycle
regulation. Reduced levels of transcription from this gene, APITD1,
present as an option for the cell to escape normal regulation during
tumorigenesis.
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In silico mapping
In order to identify a putative gene in the neuroblastoma tumour
suppressor gene candidate region on chromosome 1p36.22, UCSC
Genome Browser August 2001 chromosome 1 draft sequence
(URL:http://genome.ucsc.edu) was examined for transcripts, sug-
gested by more than one gene prediction program, within the
500kb tumour suppressor gene candidate region. Sequence
alignment, open reading frame (ORF) prediction and primer
selection were performed using the DNASTAR sequence analysis
software (LASERGENE, Madison, WI, USA), or the OLIGO primer
analysis software v.6 (Molecular Biology Insights, Cascade, CO,
USA). For promoter analysis, genomic sequence from the UCSC
contig assembly was analysed using the BDGP Neural Network
Promoter Prediction program (URL:http://www.fruitfly.org/seq_-
tools/promoter.html), and the CpG island prediction function of
the MethPrimer program (URL:http://itsa.ucsf.edu/~urolab/meth-
primer) (Li and Dahiya, 2002). In order to analyse conservation of
the APITD1 gene, the TIGR gene indices (URL:http://www.ti-
gr.org), which contain genomic sequences from a variety of
organisms, were searched for expressed sequences translated in all
reading frames, with significant similarity to the predicted protein
from APITD1.
RNA purification
Total RNA was extracted from neuroblastoma tumour samples
using the Qiagen RNeasy kit for isolation of total RNA from animal
tissues (QIAGEN, Valencia, CA, USA). For extraction of total RNA
from cell pellets of neuroblastoma cell lines containing approxi-
mately 10
7 cells, the Qiagen RNeasy kit for isolation of total RNA
from animal cells was used. An additional DNase I digestion
procedure (QIAGEN) was included in the isolation of RNA to
remove contaminating DNA according to the instructions in the
protocol.
Reverse transcription
cDNA from neuroblastoma tumour samples and cell lines was
made using SuperScriptt II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA), following the protocol for first-strand
synthesis with 1mg of total RNA and 0.5ml of random hexamers
(Promega, Madison, WI, USA).
Northern blot
Total RNA (10mg) from the neuroblastoma cell lines SK-N-AS and
SH-SY5Y was subjected to Northern blotting using the North-
ernMax
TM Kit (Ambion, Inc., Austin, TX, USA) and nylon
membranes (Ambion). Primer sequences for amplification of an
APITD1 probe were chosen with the forward primer in exon 2 (50-
AAACAGACCATTGCGGCCATT-30) and the reverse primer in
exon 5 (50-TTCCAAGCGGCGAGGG-30); thus, the probe was
complementary to both transcript versions of APITD1. Proper
normalisation of the relative abundance of total RNA in the panel
was assessed using primers for amplification of beta actin (ACTB):
(forward primer) 50-TCATGAAGTGTGACGTTGACATCCGT-30
and (reverse primer) 50-CCTAGAAGCATTTGCGGTGCACGATG-
30. The primer pairs were synthesised by Invitrogen. cDNA from
SK-N-AS was amplified with these primer pairs with an initial
denaturation at 951C for 1min, followed by amplification for 35
cycles of 30s at 951C, 30s at 551C and 2min at 721C. The PCR
products were separated on an agarose gel and amplification
products of the appropriate length were cut out from the gel and
purified using the QIAquick gel extraction kit (QIAGEN). The
hybridisation probes were then labelled with [alpha-
32P]cytosine
using the Megaprime
TM DNA labelling system (Amersham,
Piscataway, NJ, USA). Hybridisation was performed overnight at
421C, and the film was exposed for 3–4 days before detection after
hybridisation with APITD1 probe and 1 day after hybridisation
with the ACTB probe.
Semiquantitative expression analysis
The tissue-specific expression of the two transcripts of the APITD1
gene was analysed by amplification of commercially available
cDNA from CLONTECH’s Multiple Tissue cDNA Panels (CLON-
TECH, Palo Alto, CA, USA) and from OriGene (OriGene
Technologies, Inc., Rockville, MD, USA), using two primer pairs.
The primer pairs are shown in Figure 1 and listed in Table 1 as
APITD1-Expr A-B. Amplification of ACTB was performed as an
internal control with the same primer pair that was used for
amplification of the ACTB probe for Northern blotting. PCR assays
were performed with an initial denaturation at 951C for 1min,
followed by amplification for 30 cycles (ACTB) or 35 cycles
(APITD1 transcripts) of 30s at 951C, 30s at 541C and 2min at
721C. All reactions were conducted in a total volume of 50ml. The
expression of APITD1 was also determined in cDNA reverse
transcribed from various primary tumour samples and neuro-
blastoma cell lines (SK-N-AS, IMR-32, SK-N-F1, SK-N-BE(2) and
SH-SY5Y). Additional reactions were performed with control
tissues and primer pairs located in varying parts of the predicted
transcripts, in order to determine which exons are present in the
mature mRNA (Table 1; APITD1-Expr 1–6). We have also analysed
the possibility of APITD1 being a part of the adjacent gene CORT.
Therefore, two primer pairs were designed, with the forward
primer located in APITD1 exon 4 or 5, respectively, and with the
reverse primers in the coding sequence of CORT (Table 1; APITD1-
Expr 7–8). These primer pairs were used in attempts to amplify
cDNA by reverse transcriptase–PCR (RT–PCR) at different PCR
conditions.
Real-time PCR expression analysis
Primers and probes for amplification of both APITD1 transcripts
were designed spanning intron 1. They were ordered through the
Applied Biosystems ‘TaqMan
s Assays-by-Design
SM Gene Expres-
sion Service’ facility (URL:http://myscience.appliedbiosystems.-
com). TaqMan primers and probe for GUSB (b-glucuronidase)
were derived from Applied Biosystems ‘TaqMan
s Assays-on-
Demand
TM Gene Expression Products’ and amplification of GUSB
was used as an internal control for the integrity and relative
amount of mRNA. The real-time PCR reactions were performed
using an ABI PRISM
s 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). The mean CT values
for duplicate samples of neuroblastoma cell lines or neuroblastoma
tumours were used to calculate the amount of both transcripts
from a standard curve. The calculated expression levels were then
normalised to the amount of GUSB in each sample in order to
achieve a relative expression amount. This relative expression
amount of both transcripts in a group of four stage 2 tumours from
children with no residual evidence of disease was compared with a
two-sample t-test to a group of six stage 3 or stage 4 tumours from
children who had died of the disease.
Hybrid panel mapping
In order to assure the chromosomal localisation of the APITD1
gene, we used the NIGMS human/rodent somatic cell hybrid
mapping panel #2, version 3 (Coriell Institute, Camden, NJ, USA).
The primer pair for amplification of exon 4 (Table 1; APITD1-Exon
4) was used in amplification reactions, with 100ng DNA from
hybrid cells representing all human chromosomes, for 30 cycles
(30s at 951C, 30s at 551C and 1min at 721C). PCR products were
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and visualised under UV illumination.
In vitro transcription of mRNA
DNA fragments of the coding region of transcript A from APITD1
linked to the Sp6 promoter sequence and a polyA tail at the end of
the fragment were constructed by PCR using primers: (forward
primer) 50-ATTTAGGTGACACTATAGAAGATTGCCCAGGGTC
GGCCCGCAGTGATG-30 and (reverse primer) 50-GG(T)30
ACAATGTGGAGAATTCAGCAC-30, with IMAGE clone 4051739
(gene bank locus: BC029430) as a template. The PCR was
performed using High Fidelity Taq (Roche Diagnostics, Man-
nheim, Germany) according to the supplier’s protocol, with an
annealing temperature of 601C and 30 cycles of PCR. In all, 500ng
of the PCR product (663bp) was used as a template for in vitro
mRNA using mMESSAGE mMachine (Ambion). The procedure
was according to the supplier’s protocol using 4h incubation at
371C. The mRNA was DNase I treated for 15min at 371C and LiCl-
precipitated before size and concentration evaluation by agarose
gel electrophoresis. The control green fluorescent protein (GFP)
mRNA was produced using 500ng of EcoRI-digested Sp6-EGFP
vector as template in the in vitro mRNA reaction. The concentra-
tions of GFP mRNA and APITD1A mRNA were adjusted to be
equal and evaluated on agarose before each further experiment.
Cell culture
The neuroblastoma cell lines SK-N-BE(2) and SK-N-AS (American
Type Culture Collection (ATCC), Manassas, VA, USA), the
embryonic kidney derived cell line 293 (ATCC) and the
lymphoblast cell line K562 (ATCC) were cultured in Dulbecco’s
modified Eagle medium (Invitrogen) with 10% foetal calf serum
(Sigma-Aldrich Corp., St Louis, MO, USA) in 371C using standard
procedures. Cells with 60–80% confluence were used in transfec-
tion experiments. Immediately before the transfection procedure,
the SK-N-BE(2) cells, the SK-N-AS cells and the 293 cells were
trypsinised and washed twice with PBS, and the cell numbers and
the viability were calculated using trypan blue staining. The
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Figure 1 (A) Map of the 1p36.2 neuroblastoma tumour suppressor gene candidate region. The location of the genes is based on data from the UCSC
genome browser; April 2002 draft sequence. The homozygously deleted region on chromosome 1p in a neuroblastoma cell line, found by Ohira et al
(2000), is indicated by a dark shaded box, while the neuroblastoma SRO as defined by our group (Martinsson et al, 1995) is shown as a light grey box. The
region includes the genes UBE4B, KIF1B, PGD, APITD1, CORT, DFFA and PEX14. ICAT is located just distal of the region. APITD1 is marked with a black box.
Arrows indicate the transcriptional direction of the genes. The scale in the top is the approximate distance from the 1p-terminal, in mega base pairs. (B) The
genomic organisation of the APITD1 gene, with the two alternative first exons, is shown with intron sizes indicated in kb. The location of the primers used for
amplification of transcripts A and B from cDNA for RT–PCR expression analysis is also illustrated.
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more at the day of transfection.
Transfection
The transfection experiments were performed in a 12-well plate
using 4 10
5cellswell
 1 for SK-N-BE(2), SK-N-AS, and K562 cells
and 7 10
5cellswell
 1 for 293 cells, all in 2ml Dulbecco’s
modified Eagle medium with 10% foetal calf serum per well. For
each transfection, a total of 1.5mg of mRNA (A: 1.5mg GFP mRNA;
B: 0.3mg APITD1A mRNAþ1.2mg GFP mRNA; C: 1.5mg APITD1A
mRNA) and 5ml Lipofectamine-2000 (Invitrogen) were used. The
mRNA and the Lipofectamine-2000 were incubated for 30min in
200ml serum-free medium (Opti-MEM, Invitrogen) before being
added to the cell suspensions. The cell and Lipofectamine-
2000–mRNA complex mix was immediately divided into 96-well
plates at 10
4cellswell
 1 (SK-N-BE(2), SK-N-AS, K562) or
1.7 10
4cellswell
 1 (293) (50mlwell
 1), and incubated at 371C
for 5h before an extra 50mlwell
 1 of Dulbecco’s modified (Eagle)
medium with 10% foetal calf serum was added. The cells were
incubated for 1–4 days at 371C for cell growth studies.
Cell growth studies
After incubation for 1, 2, 3 and 4 days, respectively, at 371C, 20ml
of CellTiter96 AQueous One Solution Cell Proliferation Assay
(Promega) was added to each 96-well plate with 100ml cell
suspension. For each experiment, four separate wells were tested at
each time point. The mix was incubated in the dark at 371C for 4h
before the absorbance at 490nm was evaluated in an ELISA reader.
The cell number in each well was calculated using a standard curve
with known cell numbers using the same procedures as above. The
mean number of cells per well was calculated for each experiment
at each time point. At 1 day after transfection, the transfection
efficiency was evaluated using fluorescence microscopy, by
counting the number of green cells in the GFP mRNA experiments.
Experiments comparing different mRNA:s were performed from
the same batch of cells and treated equally all through the
experimental procedure.
Table 1 PCR primers used in this study
Amplified sequence Primer Primer sequence Length of fragment (bp) Annealing T
APITD1-Promoter I FP 50-CTTGTGGTCCCAGCTACTTG-30 452 52
RP 50-TTCCAGTCGGGTGTAGAGG-30
APITD1-Promoter II FP 50-AGGTCACGGGTCGTTCACTC-30 469 53
RP 50-GCGGCCAGGTCGGATT-30
APITD1-Exon 1A FP 50-CGTGTTTCGCGGAGAGTGGTGCTC-30 566 65
RP 50-CCAGCGCAGGCCAGGGTCCAG-30
APITD1-Exon 1B I FP 50-GTGCTGGGAGGCGGTTTC-30 438 65
RP 50-GCCCGCAGTTACCCTGACAA-30
APITD1-Exon 1B II FP 50-GGCCCAGAGCTCGTCCTTAGATGT-30 514 55
RP 50-TAAAATGTAAAGGCGAAGTGTCAA-30
APITD1-Exon 2 FP 50-ACTTGAAAAGCCACTCAGCCATTA-30 400 55
RP 50-ACGAAGAACGCATGAGGATGATAA-30
APITD1-Exon 3 FP 50-AAGGGTGAAGGGCTCTGGGAAGGA-30 429 58
RP 50-CACCGTGATTGAAGGAGGCGTCAT-30
APITD1-Exon 4 FP 50-TAATTGGGGTCTTAGGAACTTCAC-30 434 55
RP 50-ATTGGCTTAGCAAGATCCATCATA-30
APITD1-Exon 5 I FP 50-TAACCCAGGCTTTGGCTTTTCTAC-30 448 58
RP 50-AGCTTTGGCAGTTAACAATGTGGA-30
APITD1-Exon 5 II FP 50-CCGCTTGGAAAGTGCAGCCTTCTA-30 462 58
RP 50-CATATGCCCTTTTACCTGGTGACC-30
APITD1-Expr 1 (exon 1A-1B) FP 50-GAGGAGCAGCAGCGATTCTC-30 584 —*
RP 50-CGCGTTTCTTCAGTCCGTC-30
APITD1-Expr 2 (exon 1A-1B) FP 50-AGGGCGGAGCTGCGTACTTT-30 208 —*
RP 50-GGTCCAGCCGCGTTGC-30
APITD1-Expr 3 (exon 1A-3) FP 50-AGGAGGAGGCGGAGA-30 202 54
RP 50-GCAAACATTTCAAGGTCTTT-30
APITD1-Expr 4 (exon 2-3) FP 50-GGGTTGTCTTTGCGAGG-30 128 54
RP 50-TTGCAAACATTTCAAGGTCT-30
APITD1-Expr 5 (exon 2-4) FP 50-GCTAAAGGCAGCAGTTCAC-30 213 55
RP 50-CTCCTCCTGGCTAAGAGCTT-30
APITD1-Expr 6 (exon 4-5) FP 50-AGATGTGAAGCTCTTAGCCA-30 190 54
RP 50-CGGCGAGGGACTTTA-30
APITD1-Expr 7 (exon 4-CORT) FP 50-ATTTTGCCAAAGACCTTGA-30 531 —*
RP 50-TGTCATTACACTTGCGTGAG-30
APITD1-Expr 8 (exon 5-CORT) FP 50-TAAAGTCCCTCGCCGCTTGG-30 133 —*
RP 50-AGGAGGCCGGGGGACAAT-30
APITD1-Expr A (exon 1A-5) FP 50-CGAGGAGCAGCAGCGATTCT-30 425 54
RP 50-CGGCGAGGGACTTTA-30
APITD1-Expr B (exon 1B-5) FP 50-ACTGAAGAAACGCGGGAATG-30 507 54
RP 50-CGGCGAGGGACTTTA-30
Column 1: amplified sequence; Promoter I and Promoter II are overlapping primer pairs, which together cover 800bp before the initiation codon in transcript A; Exon 1B I and Exon
1B II cover the starting exon (1B) in transcript B together; Exon 5 I and Exon 5 II cover exon 5 and approximately 500bp into the 30 UTR region; APITD1-Expr primers are located
in the exons indicated within the parantheses, and they were used for amplification of cDNA. Column 5: Annealing temperature for PCR amplification; *No PCR product was
obtained with the APITD1-Expr 1, -Expr 2, -Expr 7 and -Expr 8 primers at various temperatures, implying that exons 1A and 1B are not in the same transcript, and that APITD1 is
not in the same transcription unit as the nearby located gene CORT.
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Genomic DNA extracted by standard procedures from 44 frozen
( 701C) primary neuroblastoma tumours of all different stages
was used for sequencing analysis. The tumours were staged
according to the International Neuroblastoma Staging System
criteria (Brodeur et al, 1988, 1993). Four were stage 4S, four were
stage 1, three were stage 2a, one was stage 2b, 13 were stage 3, 15
were stage 4 and four were of unknown stages. Of the stage 3 and 4
tumours, 16 had 1p deletion, as determined by FISH and/or
microsatellite analysis. DNA was also extracted from EDTA blood,
obtained from control individuals. The sequence results from the
tumour samples were compared to the reference sequences from
the UCSC Genome Browser (chr1_29_927.b and chr1_29_927.g).
Control samples were also included in the sequencing of all exons,
according to Table 2. Primers for amplification of the coding
sequences of the gene as well as the predicted promoter sequences
are listed in Table 1. The concentration of PCR products was
estimated by comparison to a low DNA mass ladder (Invitrogen)
on an agarose gel. The PCR products were purified with ExoSAP-
IT (USB, Corp., Cleveland, OH, USA). The sequencing reactions
were made using ABI PRISM Big Dye Terminator Cycle Sequen-
cing Ready Reaction Kit (Applied Biosystems) according to
protocols. Sequencing was performed using an ABI PRISM 3100
DNA Sequencer (Applied Biosystems). Sequence analysis was
conducted using the Vector NTI sequence analysis software
(InforMax, Frederick, MD, USA). In cases where a deviation from
the reference sequence was observed, it was confirmed through re-
sequencing from the opposite direction.
RESULTS
Genomic organisation of APITD1
A gene was predicted to reside distal to the CORT gene but
proximal to the PGD gene, in the neuroblastoma tumour
suppressor gene candidate region on chromosome 1p36.22. Due
to similarity to the TFIID-31 domain in the transcription initiation
factor TAFII31 (locus name TAF9), it was denoted APITD1
(APoptosis-Inducing, TAF9-like Domain 1). Two alternative
versions of the gene were proposed from the predicted mRNA
sequences at the UCSC Genome Browser. A closer examination of a
1214bp long predicted mRNA, chr1_29_927.b (APITD1 transcript
A) showed that the sequence between bases 588 and 1111 is
identical to exon 2 of the nearby located gene CORT and the last
103 bases in the predicted transcript between bases 1112 and 1214
is probably not a transcribed genomic sequence. Using RT–PCR,
we demonstrated that exon 2 of CORT is not included in the
APITD1 transcript A; thus a 587bp long transcript remains
(Figure 2). A 1331bp long transcript, chr1_29_927.g, with an
alternative first exon was also predicted (APITD1 transcript B)
(Figure 2). Sequence alignment of these transcripts against
genomic sequences from the public databases determined the
genomic structure of APITD1 to consist of six exons spread over
approximately 13kb (Figure 1). Two CpG islands with a GC
content of more than 80% were identified preceding and
overlapping the first exons of both transcript versions of the gene.
A possible transcription promoter was predicted to reside
approximately 200bp prior to exon 1A. The longest ORF in
transcript A stretches from base 135 to 548 and it encodes a
hypothetical protein of 138 amino acids with a molecular weight of
16kDa (Figure 2). The translation start site in this transcript is set
within the correct context for translation initiation with a purine at
 3 and G at þ4 (Kozak, 1996). In transcript B, however, there is
no ORF with the optimal translation initiation context. Two ORFs
of adequate length exist in the transcript, both with a C at position
þ4 instead of the consensus nucleotide G. The first ORF is set
between base 266 (in exon 1B) and 631. No related human
sequences are retrieved through BLAST searches of nucleotide and
protein databases, with the hypothetical protein translated from
this ORF. The other ORF runs in the same reading frame as the
ORF in transcript A; it is located between base 736 (in exon 2) and
1032 and it encodes for a hypothetical protein of 99 amino acids
with a molecular weight of 11kDa (Figure 2). This ORF, like the
ORF in transcript A, encodes an amino-acid sequence with
homology to the TFIID-31 subunit of the transcription initiation
factor TFIID, required for p53-mediated transcription activation.
The translated ORF in transcript A also displays a high sequence
similarity to translated expressed sequences from other organisms
than human (Figure 3).
Northern blot
Northern blot hybridisation of neuroblastoma cell lines SK-N-AS
and SH-SY5Y with use of a radio labelled APITD1 probe
identified two transcripts of approximately 1.5 and less than 1kb
Table 2 DNA variations in APITD1 sequence
Tumours Controls
DNA variation
Genomic
location
Screened
number HetZ
HomZ/HemZ
for non-ref.
seq. allele
HomZ/HemZ
for ref. seq.
allele
Screened
number HetZ
HomZ for
non-ref.
seq. allele
HomZ for
ref. seq.
allele
c.1-464 T4C Promoter
a 44 30 (68%) 6 (14%) 8 (18%) 38 18 (47%) 8 (21%) 12 (32%)
c.1-290 T4C Promoter
a 44 29 (66%) 6 (14%) 9 (20%) 42 14 (33%) 14 (33%) 14 (33%)
c.1-225 G4A Promoter
a 44 1 (2%) 0 43 (98%) 42 0 0 42 (100%)
c.1-53 C4T Promoter
a 44 2 (5%) 0 42 (95%) 38 1 (3%) 0 37 (97%)
c.1-36 G4C
b 50 UTR
c 44 10 (23%) 0 34 (77%) 38 7 (18%) 2 (5%) 29 (76%)
c.1-25 G4C
b 50 UTR
c 44 10 (23%) 0 34 (77%) 38 7 (18%) 2 (5%) 29 (76%)
c.1-644 A4G5 0 UTR
d 44 29 (66%) 8 (18%) 7 (16%) 48 12 (25%) 21 (44%) 15 (31%)
c.1-316 A4G5 0 UTR
d 44 10 (23%) 34 (77%) 0 46 2 (4%) 42 (91%) 2 (4%)
c.277-(14-5) insT Intron 4
b 44 6 (14%) 0 38 (86%) 43 10 (23%) 0 33 (77%)
c.665 A4G3 0 UTR
c 44 10 (23%) 33 (75%) 1 (2%) 46 7 (15%) 37 (80%) 2 (4%)
aThe UCSC Genome Browser August 2001 Chromosome 1 draft sequence was used as a reference sequence, with the A in the initiation codon starting at base 135 in transcript
A (chr1_29_927.b) denoted nucleotide 1.
bLinkage disequilibrium is present between the two variations.
cTranscript A was used as a reference.
dTranscript B (chr1_29_927.g)
was used as a reference. Base number 1 was assigned to the A base of an initiation codon starting at base 736 in the transcript. Column 3: number of tumour samples screened
for each variation. Columns 4–6: number of tumour samples with each observed allele and frequency of the allele in the screened population; HetZ, heterozygote; HomZ,
homozygote; HemZ, hemizygote; ref., reference; seq., sequence. Column 7: number of control samples screened for each variation. Columns 8–10: number of control samples
with each observed allele and frequency of the allele in the screened population; HetZ, heterozygote; HomZ, homozygote; ref., reference; seq., sequence.
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srespectively. The higher molecular weight transcript was more
abundant (Figure 4).
Transcript variants from the APITD1 gene
In order to establish which exonic sequences are transcribed from
the APITD1 gene, RT–PCR was performed on cDNA extracted
from kidney, foetal kidney, brain, foetal brain and stomach, using
primer pairs located in various exons (Table 1). Attempts to
amplify the sequence between exons 1A and 1B failed, implying
that these exons are located in different transcripts. All other
combinations of amplification that are listed in Table 1 resulted in
PCR products of the expected sizes (data not shown). There was no
amplification product in the RT–PCR reactions when forward
1  GAGGCAGGGCGGAGCTGCGTACTTTGTCCGCCCGCGCGGCCCGTCGCTCGCGCCGC
GGCGGGAAAATCCGACCTGGCCGCGCACCACCGCCCCTTCTCCGCCCTCCTGCCTTTGCCCAGGGTCGGCCCGCAGTGATGGAGGAGGAG
GCGGAGACCGAGGAGCAGCAGCGATTCTCTTACCAACAG...
AGGCTAAAGGCAGCAGTTCACTATACTGTGGGTTGTCTTTGCGAGGAAGTT
GCATTGGACAAAGAGATGCAGTTCAGCAAACAGACCATTGCGGCCATTTCGGAGCTGACTTTCCGACAGTGTGAAAATTTTGCCAAAGAC
CTTGAAATGTTTGCAAGACATGCGAAAAGAACCACAATTAACACTGAAGATGTGAAGCTCTTAGCCAGGAGGAGTAATTCACTGCTAAAA
TACATCACAGACAAAAGTGAAGAGATTGCTCAGATTAACCTAGAACGAAAAGCACAGAAGAAAAAGAAGTCAGAGGATGGAAGCAAAAAT
TCAAGGCAGCCAGCAGAGGCTGGAGTGGTGGAAAGTGAGAATTAAAGTCCCTCGCCGCTTGGAAAGTGCAGCCTTCTACAGGTAGAGCCA
GCGGTTTCCGCGGCAACGCGGCTGGACCCTGGCCTGCGCTGGCTGGGGAGGAAGCGGTTCTAGGGGAGCGTGCGGGCGCCGGGGTCCGGC
GACGAGAGGCCACCTTCTGGCCTTGCGATGAATCCTCGGTTTCCCCTTCTCAGATGGGGTTTTCGTGAGGGTACAACGTCGGCATTAGAC
ATTCCAGGTGACGCCCGTACGCGGTGGGCGGTTCGGGCCGGAGCTCTGGAACGCTGGCCCTGGAGGCGTCGACCCCTCGTTACTGATGCA
GGGACGCGGTGCGGACCAGTCAGGCCCAGAGCTCGTCCTTAGATGTGGGTTCGAATCTCTGCCCCGCCAACTTGTGATCGTATCGACTCG
GCCCAGACGCAATTTTCTTCTCTGCAAAATCGTCATAAGAATAATCACTTGTCAGGGTAACTGCGGGCATCCCATTCGTTCCTTTCATCA
GCGCCGGGCATATGGGGCGTCAGAGGCTGAGAACGTTGCCGTGAAGAGGCTTAAAAGCAAGACCCGGAGTGGCGACCTTAAAGAGGACGG
ACTGAAGAAACGCGGGAATGAGCTCCAGACGCGGGAGTTTCCTCTCTACAAAGTTACACTGCAGCAGCTGTCTACCCTGCCCCTTGTCTT
TTGAGAAGTTCAAACCTTCAGAAAAGTTGCAAGAACACG...
AGGCTAAAGGCAGCAGTTCACTATACTGTGGGTTGTCTTTGCGAGGAAGTT
GCATTGGACAAAGAGATGCAGTTCAGCAAACAGACCATTGCGGCCATTTCGGAGCTGACTTTCCGACAGTGTGAAAATTTTGCCAAAGAC
CTTGAAATGTTTGCAAGACATGCGAAAAGAACCACAATTAACACTGAAGATGTGAAGCTCTTAGCCAGGAGGAGTAATTCACTGCTAAAA
TACATCACAGACAAAAGTGAAGAGATTGCTCAGATTAACCTAGAACGAAAAGCACAGAAGAAAAAGAAGTCAGAGGATGGAAGCAAAAAT
TCAAGGCAGCCAGCAGAGGCTGGAGTGGTGGAAAGTGAGAATTAAAGTCCCTCGCCGCTTGGAAAGTGCAGCCTTCTACAG
CCTAGAAATGCATATGGCTGCAAAGGAAACTTTGAAGGGTTAAATAGAGATTTAAAAAAATAAAATAAAAAGGCTGGGCTAGGGTGCTTT
TTGTGCTGAATTCTCCACATTGTTAACTGCCAAAGCTAGTTTTAGAGAATGAGAAAGTCTTAAGCAAAATACTCCCAGGTCTCACTCCAG
AACATAAAAATGGTGTGTGATCAAATGGTATATATTAGAAATTACATCTGTTGTAATTAAAATTGTGTGAG
1
91
181
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541
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811
Exon 1B
Exon 1A
M  Q  F  S  K  Q  T  I  A  A  I  S  E  L  T  F  R  Q  C  E  N  F  A K  D
A  E  T  E  E  Q  Q  R  F  S  Y  Q  Q  
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R  L  K  A  A  V  H  Y  T  V  G  C  L  C  E  E  V
M  E  E  E  
L  E  M  F  A  R  H  A  K  R  T  T  I  N  T  E  D  V  K  L  L  A R  R  S  N  S  L  L  K
Y  I  T  D  K  S  E  E  I  A  Q  I  N  L  E  R  K  A  Q K  K  K  K  S  E  D  G  S  K  N
S  R  Q  P  A  E  A  G  V  V  E  S  E  N
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1261
Figure 2 The two alternative transcript versions of the APITD1 gene. Both transcripts share exons 2–5, but they differ in the starting exons and in the
30UTR sequences. Exon 1A is located approximately 160bp upstream of exon 1B in the genomic sequence. The translated sequence from the ORF in
transcript A and the in-frame ORF in transcript B, which starts immediately prior to the putative TFIID-31 domain, is shown. The amino-acid sequence with
significant similarity to the TFIID-31 domain is marked in bold face and italics. The last 622bp of transcript A (chr1_29_927.b), which consists of exon 2 from
the nearby located gene CORT and noncoding genomic sequence, is not shown.
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sprimers, located in APITD1, were used with reverse primers
located in CORT. Thus, our data show that APITD1 is a gene
distinct from CORT.
Tissue-specific expression
Both APITD1 transcripts were ubiquitously expressed in all tested
normal tissues, with an especially high level of expression in the
adult testis of both transcripts and in the adult kidney of transcript
B. A low level of expression of transcript B was detected in the
peripheral blood leukocyte and spleen from adult tissues, and in
the skeletal muscle and thymus from foetal tissues (Figure 5A).
The expression of transcript A was generally higher in foetal
tissues than in adult tissues, while the opposite situation occurred
for transcript B.
APITD1 expression in tumour samples and neuroblastoma
cell lines
The APITD1 transcripts were either not expressed or only present
at low levels in both neuroblastoma tumours (Figure 5B) and a set
of various tumour types (Figure 5C). A PCR product of length
shorter than 507bp was also observed in the amplification reaction
of transcript B in some tumours. This product was analysed by
sequencing, and was shown to be an amplification product
originating from a gene on chromosome 16, with a partial
sequence homology to the primer sequences (data not shown).
The expression of both transcripts was markedly reduced
compared to the level of expression in normal tissues and in the
neuroblastoma cell lines, with the exception of IMR-32, which had
a weak expression of both transcripts.
A more sensitive screening by quantitative real-time PCR
revealed that the mean relative expression level of transcript A
was significantly lower in the high-stage tumours (mean 0.07; s.d.
0.03) than in the low-stage tumours (mean 0.35; s.d. 0.17)
(P¼0.0022). There was also a significant difference (P¼0.0016)
in the relative mean expression levels of transcript B between the
high-stage tumours (mean 0.74; s.d. 0.26) and the low-stage
tumours (mean 1.85; s.d. 0.43). The relative amount of the APITD1
transcripts was considerably higher in the cell lines than in the
tumour samples (Table 3).
Hybrid panel mapping
PCR products of the expected size (434bp) were obtained in the
chromosome 1 cell hybrid and in the human cell line control
exclusively (Figure 6).
Human         
Pig  [92%]
Cattle  [83%] 
Mouse  [77%]
Rat  [76%]
Xenopus [69%]
G gallus  [67%]
R trout  [63%] 
Pig
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Human         
Mouse         
Rat           
Xenopus
G gallus
R trout
 QQRFSYQQRLKAAVHYTVGCLCEEVALDKEMQFSKQTIAAISELTFRQCENFAKDLEMFARHAK 
QQRFSYRQRLKAAVHYTVGCLCEEVASDKDMPFSKQTIAAISEATFRQCENFAKDLEMFARHAK 
QQRFSYLQRLKAAVHYTVGCLCEEVASDKDMQFSKQTIAAISEVTFGQCENFAKDLEMFARHAK 
-QEFSHRQRLKAAVHYTVGCLCQEVTLNKQVNFSKQTIAAISEVTFRQCENFAKDLEMFARHAK 
---------------------------------------------------FAKDLEMFARHAK
 EEHFSRTQRLKAAVHYVVGSLCQEVADDKEIDFSKQAIAAISEITFRQCESFAKDLEIFARHAK 
EQRELLIQRLRAAVHYTTGCLCQDVAEDKGVLFSKQTVAAISEITFRQCENFARDLEMFARHAK 
-------QRLKAAVHYTVGRLCQSIGEDHQKEFSRQVIAAIAETTFRQCDIFAKDLEAFARHAK
++     QRL+AAVHY  G LC+ +  +    FS+Q +AAI+E TF QC+ FA+DLE FARHAK
RSTINTEDVKLLARRSNSL---------------------------------------------
RSTINTEDVKLLARRSHSLLKYITEKNEDIAQLNLEKKAKKKKKLEDENRNSVESAEAGVEESE
 RTTINTEDVKLLARRSNSLLKYITDKSEEIAQINLERKAQKKKKSEDGSKNSRQPAEAGVVESE 
 RSTVTTEDVKLLARRNNSLLKYITEKNEEIAQLNLKGKAKKKRKPEDESRSSRE----------
 RSTITTDDVKLLLRRSNSLLKYITEKNKEIAQLNLEQKAKKKRKSED-----------------
RTTINMDDVKLLARRSRSLYAHISKCSDEIAANSLEQKEKKKKKSVSGGNVSR-----------
RSTITSEDVKLLARRSNSLLKYITQKSDELASSNMEQKEKKKKKSSAAKGRKTEENETPVTESE
RSTVSVEDVKLTARRSTALANFIQRKSEEIASANQEQRDTRKK---------------------
R+T+  +DVKL  RR+ +L  +I   ++++A  + + +  +K+K        +  E  V ESE 
Figure 3 Conserved amino acids in the translated APITD1 transcript A ORF. The first nine amino acids in the translated ORF did not align to the translated
expressed sequences from other organisms in the TIGR database, and they are not shown. Percent identity with the human sequence is shown within
brackets after the name of each organism. Residues which are identical or chemically similar to the human amino-acid sequence are highlighted in grey. The
residues which are identical or similar among all aligned sequences are indicated under the alignment, and the TFIID-31 similar domain is framed.
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Figure 4 Transcript size of the APITD1 gene. Northern blot analysis of
total RNA isolated from the neuroblastoma cell lines SK-N-AS and SH-
SY5Y. The blot was hybridised with a radio labelled probe. (A) APITD1.( B)
ACTB internal loading control.
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The mRNA transfection experiments showed that by adding 1.5mg
of APITD1A mRNA to the neuroblastoma cell line SK-N-AS the cell
number was reduced by 70% after 24h, and by 90% after 2–4 days
of incubation, compared to GFP mRNA-transfected cells. If 0.3mg
APITD1A mRNA was mixed with 1.2mgo fGFP mRNA, the
reductions in cell numbers after 24h were 40% and 65% after 2–4
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Figure 5 RT–PCR expression analysis of transcripts A and B in APITD1. Amplification of APITD1 transcript A and APITD1 transcript B in each sample is
compared to the amplification of ACTB.( A) Fairly ubiquitous expression of both transcripts in a set of normal adult and foetal tissues (CLONTECH). Lanes
1–24, PCR products from the indicated tissues. (B) Reduced expression of APITD1 gene products in neuroblastoma tumours of different stages compared
to neuroblastoma cell lines and adult and foetal normal tissues (OriGene). The outcome of the patients, the stage of neuroblastoma and the status of
chromosome 1p is indicated above the upper panel; NED, no evidence of disease; DOD, dead of disease; 1, 2, 2a, 3, 4 and 4S, stages of neuroblastoma;  ,
negative for 1p deletion; þ, positive for 1p deletion; 7, uncertain result (based on FISH and microsatellite analysis). Lanes 1–17, neuroblastoma tumours;
lanes 18–26, neuroblastoma cell lines and normal tissues as indicted above the panel. (C) Reduced expression of APITD1 gene products in various tumours.
Lanes 1–14, tumours of various types as indicated above the panel.
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sdays (Figure 7A). After 2–3 days, the number of SK-N-BE(2) cells
in the 1.5mg APITD1A-transfected experiment was 60–70% below
the GFP control and after 4 days the reduction was 80%. The SK-N-
BE(2) cells transfected with a mix of 0.3mg APITD1A mRNA and
1.2mg GFP mRNA showed an increase in cell numbers by 20–30%
compared to the GFP-transfected cells after 3–4 days (Figure 7B).
Table 3 Amounts of APITD1 transcripts measured by quantitative real-time PCR
Cell lines APITD1 A APITD1 B
SK-N-AS 0.70 1.61
SK-N-DZ 1.17 3.14
SK-N-SH 2.07 3.73
SK-N-BE(2) 2.06 2.41
SK-N-F1 0.79 4.28
SH-SY5Y 1.65 2.21
Cases Group Stage 1p-del MYCN 17q gain Ploidi Outcome
18F8 0.60 2.37 F 2A neg 4n NED
20S9 0.23 1.32 F 2 neg neg NED
23S4 0.36 1.77 F 2 neg neg 3n NED
25S9 0.22 1.92 F 2 neg neg NED
4F1 0.12 0.76 UF 4 neg neg pos 2n DOD
10S2 0.08 0.45 UF 4 pos/neg pos DOD
13S0 0.06 1.00 UF 4 pos pos pos DOD
13S1 0.09 0.39 UF 3 pos pos pos DOD
15S3 0.06 0.89 UF 4 neg/pos neg pos DOD
17S2 0.05 0.94 UF 4 neg neg DOD
Column 2: relative amount of APITD1 A expression. Column 3: relative amount of APITD1 B expression. Column 4: F, favourable; UF, unfavourable; based on prognostic markers
and the outcome of the disease. Columns 6–8: 1p-del, 1p-deletion; MYCN, MYCN amplification; 17q gain, neg, negative; pos, positive; neg/pos; ambiguous results based on
microsatellite marker analysis (according to Martinsson et al, 1995) and FISH, empty cells, not determined. Column 10: NED, no evidence of disease DOD, dead of disease.
434 bp
10 11 12 13 14 15 1617 18 19 20 21 22 X Y 123456 7 89
H
u
m
a
n
C
h
i
n
e
s
e
 
h
a
m
s
t
e
r
M
o
u
s
e
Figure 6 PCR amplification of APITD1 exon 4 in a human/rodent somatic cell hybrid mapping panel. Amplification products of the appropriate size are
obtained in the chromosome 1 cell hybrid and in the human cell line control exclusively.
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Figure 7 Comparative growth curves of cell lines after transfection of 1.5mg GFP mRNA; 0.3mg APITD1A mRNAþ1.2mg GFP mRNA or 1.5mg APITD1A
mRNA, respectively. (A) SK-N-AS (neuroblastoma). (B) SK-N-BE(2) (neuroblastoma). (C) K562 (lymphoblast). (D) 293 (transformed embryonal kidney).
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reduction in cell numbers of 20–30% could be seen after 2–4 days.
Also, in this experiment, there was a slight increase in the number
of cells transfected with the lower concentration of APITD1A
mRNA compared to the GFP-transfected control cells (Figure 7C).
In 293 cells, an equal reduction in cell numbers could be seen after
2 days (60–70%), for both APITD1A mRNA experiments
compared to control cells. After 3–4 days of incubation, the
experiment using 1.5mg APITD1A mRNA still showed 60–70%
reduction, while the 0.3mg APITD1A mRNA experiment showed
40% reduction compared to control cells (Figure 7D). The
transfection efficiency of GFP mRNA for SK-N-AS, SK-N-BE(2)
and 293 cells was determined to 90% and for K562 to 60%
fluorescence microscopy 24h after transfection (Figure 8).
Mutation analysis of APITD1
No changes were found in the coding sequence of APITD1 in the
tumour samples when compared to the reference samples.
Variations that were identified in noncoding sequence are listed
in Table 2.
DISCUSSION
Mutations in the tumour suppressor gene TP53, which has
implications for tumorigenesis in many other tumour types (Nigro
et al, 1989; Levine et al, 1991), are rare in primary neuroblastoma
tumours (Imamura et al, 1993; Komuro et al, 1993; Vogan et al,
1993; Hosoi et al, 1994). A frequent characteristic of mainly
advanced neuroblastoma tumours is deletion of the distal part of
chromosome region 1p, indicating that this is the location of a
neuroblastoma tumour suppressor gene (NBS; OMIM 256700). Our
group and others have tried to narrow down the consensus region
of the NBS locus (Caron et al, 1995; Maris et al, 1995; Martinsson
et al, 1995, 1997; White et al, 1995; Ichimiya et al, 1999; Bauer et al,
2001; Caron et al, 2001; Ejeska ¨r et al, 2001; Maris et al, 2001;
Spieker et al, 2001; White et al, 2001). In 2000, Ohira et al
presented the first case of a homozygous deletion in the region in a
neuroblastoma cell line. The 500kb deletion partly overlaps the
most proximal part of the consensus LOH region determined by us
in our set of tumours. We have previously screened all annotated
genes within this 500kb region for mutations in neuroblastoma
patients (Ejeska ¨r et al, 2000; Abel et al, 2002; Krona et al, 2003). In
this study, we have further explored this genomic region by the
characterisation of a predicted gene, APITD1.
The coding sequence of the predicted gene in the neuroblastoma
tumour suppressor candidate region on chromosome 1p36.22 is
transcribed into alternative 50 end mRNAs. The predicted amino-
acid sequence of this gene, which we denoted APITD1 (Apoptosis-
Inducing, TAF9-like Domain 1), is similar to the human TATA
box-binding protein-associated factor TAFII31, a component of
TFIID. TAFII31 has been identified as a critical protein required for
p53-mediated transcriptional activation (Lu and Levine, 1995). The
ATG start codon of the APITD1 A transcript occurs in a strong
context, RNNatgG, where R is a purine (Kozak, 1996), suggesting
that translation from this mRNA is active. However, despite the
fact that the B transcript was shown to be ubiquitously expressed,
the translational status of this mRNA must be considered with
caution since there is no translation initiation site headed by a
strong ATG codon (Kozak, 1996) in this transcript.
We have shown that expression of APITD1 transcript A is
generally elevated in a set of eight foetal tissues compared with the
same tissues from adults, with the most notable difference
observed in cDNA extracted from brain and heart tissue, where
the foetal expression was markedly elevated compared to the adult
counterparts. Observed variations in band intensity should be
reliably attributed to true differences in target mRNA abundance
since the cDNA panel used has been previously normalised to the
expression levels of at least four different housekeeping genes.
Furthermore, replicate experiments resulted in comparable band
intensities for each sample. The expression in neuroblastoma
tumours of both transcripts was low when compared with
neuroblastoma cell lines and normal tissues. Furthermore, a more
sensitive quantification by real-time PCR revealed that the level of
expression of both APITD1 transcripts was significantly reduced in
a group of high-stage tumours from patients who had died from
the disease when compared to a group of low-stage tumours from
patients with no residual evidence of disease. The relatively strong
expression of APITD1 transcript A in foetal tissues appears in
strong contrast to the low expression in embryonal neuroblastoma
tumours. We therefore propose that timed expression of APITD1 is
important for the proper differentiation of foetal cells. On the
other hand, expression of both APITD1 transcripts was also almost
A
B
C
Figure 8 Expression of GFP in transfected cells shows that the mRNA
has been introduced into the cells. (A) K562 (lymphoblast). (B) SK-N-AS
(neuroblastoma). (C) SK-N-BE (neuroblastoma).
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(kidney) and paediatric (teratomas, Wilms’ tumours, B-cell
lymphomas and a pheochromocytoma). This indicates that
APITD1 can have a more general significance for regulation of
the cell cycle in normal cells.
We could show that APITD1A mRNA has a strong effect on cell
growth in neuroblastoma cells (SK-N-BE(2) and SK-N-AS). The
effect was dose dependent in SK-N-AS cells where the number of
viable cells was decreased by 90% 2 days after transfection in the
APITD1A mRNA experiment compared to cells where an equal
amount of GFP mRNA had been added. If four out of five of the
APITD1A mRNA was exchanged to control mRNA, the decrease
was 65% 2 days after transfection (Figure 7A). There was also a
clear reduction in the number of viable cells when SK-N-BE(2) was
transfected with 1.5mg APITD1A mRNA. However, when 0.3mgo f
APITD1A mRNA was used, the SK-N-BE(2) cells were even
growing faster after 3–4 days than the control cells did
(Figure 7B). The effect of APITD1A mRNA on the cells could be
due to a number of different reasons, that is, increased apoptosis,
growth arrest, or some general toxicity of the APITD1A mRNA.
The amount of mRNA added to each cell can always be argued, but
still these experiments indicate that APITD1A indeed can have a
role in an apoptotic or growth suppression pathway in neuro-
blastoma cells.
An effect could also be seen on 293 cells by adding APITD1A
mRNA, even though not quite as strong (60–70% reduction) as
neuroblastoma cells (80–90% reduction) after 4 days incubation.
This difference in effect can of course depend on a number of
reasons, like the amount of APITD1A mRNA per cell and the
specific properties of the cells of these particular cell lines.
However, one interesting thing to note is that the dose of APITD1A
mRNA does not seem to make a difference the first couple of days
after transfection in 293 cells. The difference in effect from the
different doses comes first 3 days after transfection (Figure 7D). A
difference this long after transfection might be due to the ability of
the cell to break down mRNA. In the experiment with five times as
much APITD1A mRNA, there will probably be more mRNA
molecules left longer in the cell; thus the APITD1A mRNA will have
time to affect more cells. The lymphoblast cell line K562 shows
minor differences in cell growth between APITD1A mRNA
experiments and control mRNA experiments (Figure 7C). Thus,
APITD1A mRNA does not seem to activate any cell death or
growth suppression pathway in these cells, as it seems to do in the
neuroblastoma cell lines and in the transformed embryonic kidney
cell line 293. However, these are indeed very different types of cells,
and they are likely to be defective in different cellular pathways.
Thus, we have shown that APITD1A mRNA is capable of
inducing cell death or growth suppression pathways in two
neuroblastoma cell lines. As indicated in our expression studies,
the level of APITD1 transcription in the neuroblastoma cell lines is
intrinsically not as low as in the neuroblastoma tumours, which
suggests that this is not the mechanism responsible for the
immortality of neuroblastoma cell lines. Still, since the neuro-
blastoma cell lines are known to be different from primary
tumours in many aspects (i.e. karyotype and milieu), it would not
be surprising if they turned out to have different approaches than
primary tumours to avoid the cell growth-regulating pathways of a
normal cell.
Since APITD1 has a domain with homology to the human TATA
box-binding protein-associated factor TAFII31, which has been
identified as a critical protein required for p53-mediated
transcriptional activation, expression of APITD1 might be
necessary for the induction of apoptosis in defective foetal cells
by the p53 pathway. There is also high sequence similarity between
the translated ORF of APITD1A and translated expressed
sequences from other organisms. For instance, 77 out of 83
(92%) of the amino acids in a part of this hypothetical protein are
identical to a translated nucleotide sequence from pig. By
comparison, the alignment between the hypothetical TFIID-31
domain in APITD1 and the TFIID-31 domain in TAFII31 was only
57%. Thus, it seems that APITD1 encodes an evolutionary
conserved protein motive, similar to but different from TAFII31,
in accordance with our hypothesis that APITD1 is a new member
of the family of important proteins involved in cell regulation. In
conclusion, we have characterised a novel gene, encoding a
domain similar to a p53 transcription initiation factor, in the
neuroblastoma tumour suppressor gene candidate region on
chromosome 1p. We have demonstrated a preferred foetal
expression of one transcript of the gene, which is in sharp
contrast to its very weak or absent expression observed in
neuroblastoma tumours. We have been able to show that APITD1
in fact has cell growth and/or cell death properties in
neuroblastoma cells by functional studies of the APITD1A mRNA
in cell lines. Future studies of APITD1 will be necessary to
determine if it functions as a tumour suppressor gene upstream of
TP53 and whether mutations in APITD1, although not commonly
present in neuroblastoma, might be of importance in other tumour
types.
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